{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:42:22Z","timestamp":1792651342624,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,14]]},"DOI":"10.7759\/cureus.45270","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T05:26:59Z","timestamp":1694755619000},"source":"Crossref","is-referenced-by-count":2,"title":["Multiple Myeloma and the Role of Bisphosphonates in Its Management"],"prefix":"10.7759","author":[{"given":"Nida","family":"Tanveer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shravya","family":"Pingili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya Krishna","family":"Makkena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo P","family":"Jaramillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babatope L","family":"Awosusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javaria","family":"Ayyub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan Nareshbhai","family":"Dabhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namra V","family":"Gohil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pousette","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13038","article-title":"Multiple myeloma in the marrow: pathogenesis and treatments","volume":"1364","author":"Fairfield H","year":"2016","unstructured":"Fairfield H, Falank C, Avery L, Reagan MR. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016, 1364:32-51. 10.1111\/nyas.13038","journal-title":"Ann N Y Acad Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan GJ","year":"2012","unstructured":"Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012, 12:335-48. 10.1038\/nrc3257","journal-title":"Nat Rev Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031286","article-title":"Multiple myeloma and bone: the fatal interaction","volume":"8","author":"Marino S","year":"2018","unstructured":"Marino S, Roodman GD. Multiple myeloma and bone: the fatal interaction. Cold Spring Harb Perspect Med. 2018, 8:a031286. 10.1101\/cshperspect.a031286","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau P","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, et al.. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017, 28:iv52-61. 10.1093\/annonc\/mdx096","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/cells11152308","article-title":"Bone disease in multiple myeloma: biologic and clinical implications","volume":"11","author":"Bernstein ZS","year":"2022","unstructured":"Bernstein ZS, Kim EB, Raje N. Bone disease in multiple myeloma: biologic and clinical implications. Cells. 2022, 11:2308. 10.3390\/cells11152308","journal-title":"Cells"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake MT","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008, 83:1032-45. 10.4065\/83.9.1032","journal-title":"Mayo Clin Proc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.31599","article-title":"Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro","volume":"85","author":"Henneman ZJ","year":"2008","unstructured":"Henneman ZJ, Nancollas GH, Ebetino FH, Russell RG, Phipps RJ. Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro. J Biomed Mater Res A. 2008, 85:993-1000. 10.1002\/jbm.a.31599","journal-title":"J Biomed Mater Res A"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/BF02196199","article-title":"The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats","volume":"6","author":"Russell RG","year":"1970","unstructured":"Russell RG, M\u00fchlbauer RC, Bisaz S, Williams DA, Fleisch H. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res. 1970, 6:183-96. 10.1007\/BF02196199","journal-title":"Calcif Tissue Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2020.100063","article-title":"Development and clinical application of phosphorus-containing drugs","volume":"8","author":"Yu H","year":"2020","unstructured":"Yu H, Yang H, Shi E, Tang W. Development and clinical application of phosphorus-containing drugs. Med Drug Discov. 2020, 8:100063. 10.1016\/j.medidd.2020.100063","journal-title":"Med Drug Discov"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S337925","article-title":"New progress in improving the delivery methods of bisphosphonates in the treatment of bone tumors","volume":"15","author":"Zhong Y","year":"2021","unstructured":"Zhong Y, Li S. New progress in improving the delivery methods of bisphosphonates in the treatment of bone tumors. Drug Des Devel Ther. 2021, 15:4939-59. 10.2147\/DDDT.S337925","journal-title":"Drug Des Devel Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2017.11.012","article-title":"Biology and treatment of myeloma related bone disease","volume":"80","author":"Terpos E","year":"2018","unstructured":"Terpos E, Christoulas D, Gavriatopoulou M. Biology and treatment of myeloma related bone disease. Metabolism. 2018, 80:80-90. 10.1016\/j.metabol.2017.11.012","journal-title":"Metabolism"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00788","article-title":"Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma","volume":"9","author":"Harmer D","year":"2019","unstructured":"Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. Front Endocrinol (Lausanne). 2019, 9:788. 10.3389\/fendo.2018.00788","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.12.040194.001041","article-title":"Function and activation of NF-kappa B in the immune system","volume":"12","author":"Baeuerle PA","year":"1994","unstructured":"Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994, 12:141-79. 10.1146\/annurev.iy.12.040194.001041","journal-title":"Annu Rev Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1027","article-title":"Benefits and risks of bisphosphonate therapy for osteoporosis","volume":"97","author":"Khosla S","year":"2012","unstructured":"Khosla S, Bilezikian JP, Dempster DW, et al.. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012, 97:2272-82. 10.1210\/jc.2012-1027","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.18773\/austprescr.2000.144","article-title":"Bisphosphonates - mechanisms of action","volume":"23","author":"Martin TJ","year":"2000","unstructured":"Martin TJ, Grill V. Bisphosphonates - mechanisms of action. Aust Prescr. 2000, 23:130-2.","journal-title":"Aust Prescr"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella MA","year":"2008","unstructured":"Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008, 74:1385-93.","journal-title":"Kidney Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13502","article-title":"Bisphosphonate guidelines for treatment and prevention of myeloma bone disease","volume":"47","author":"Lee OL","year":"2017","unstructured":"Lee OL, Horvath N, Lee C, et al.. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Intern Med J. 2017, 47:938-51. 10.1111\/imj.13502","journal-title":"Intern Med J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s4004","article-title":"Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients","volume":"4","author":"Chantzichristos D","year":"2008","unstructured":"Chantzichristos D, Andr\u00e9asson B, Johansson P. Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients. Ther Clin Risk Manag. 2008, 4:1371-4. 10.2147\/tcrm.s4004","journal-title":"Ther Clin Risk Manag"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.060712","article-title":"Osteonecrosis of the jaw: more research needed","volume":"21","author":"Shane E","year":"2006","unstructured":"Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S, Pendrys D. Osteonecrosis of the jaw: more research needed. J Bone Miner Res. 2006, 21:1503-5. 10.1359\/jbmr.060712","journal-title":"J Bone Miner Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8345309","article-title":"Medication-related osteonecrosis of the jaws: two center retrospective cohort studies","volume":"2019","author":"Petrovic M","year":"2019","unstructured":"Petrovic M, Jelovac DB, Antic S, et al.. Medication-related osteonecrosis of the jaws: two center retrospective cohort studies. Biomed Res Int. 2019, 2019:8345309. 10.1155\/2019\/8345309","journal-title":"Biomed Res Int"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-021-00637-3","article-title":"Nephrotic syndrome with acute kidney injury due to focal segmental glomerulosclerosis following long-term treatment with minodronate","volume":"11","author":"Morinishi T","year":"2021","unstructured":"Morinishi T, Nawata A, Konishi R, Ono E, Takaori K, Maeda S. Nephrotic syndrome with acute kidney injury due to focal segmental glomerulosclerosis following long-term treatment with minodronate. CEN Case Rep. 2021, 11:120-5. 10.1007\/s13730-021-00637-3","journal-title":"CEN Case Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"Markowitz GS","year":"2001","unstructured":"Markowitz GS, Appel GB, Fine PL, et al.. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001, 12:1164-72. 10.1681\/ASN.V1261164","journal-title":"J Am Soc Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v69i1.1518","article-title":"Bisphosphonates for osteoporosis in patients with renal insufficiency: pharmacists\u2019 practices and beliefs","volume":"69","author":"Sadowski CA","year":"2016","unstructured":"Sadowski CA, Lyder C, Yuksel N. Bisphosphonates for osteoporosis in patients with renal insufficiency: pharmacists\u2019 practices and beliefs. Can J Hosp Pharm. 2016, 69:14-22. 10.4212\/cjhp.v69i1.1518","journal-title":"Can J Hosp Pharm"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90221.x","article-title":"Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group","volume":"65","author":"Knudsen LM","year":"2000","unstructured":"Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000, 65:175-81. 10.1034\/j.1600-0609.2000.90221.x","journal-title":"Eur J Haematol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1080\/10428190601126602","article-title":"Renal failure in multiple myeloma: incidence, correlations, and prognostic significance","volume":"48","author":"Eleutherakis-Papaiakovou V","year":"2007","unstructured":"Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al.. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007, 48:337-41. 10.1080\/10428190601126602","journal-title":"Leuk Lymphoma"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-021-00971-0","article-title":"Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety","volume":"16","author":"Gopaul A","year":"2021","unstructured":"Gopaul A, Kanagalingam T, Thain J, Khan T, Cowan A, Sultan N, Clemens KK. Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety. Arch Osteoporos. 2021, 16:116. 10.1007\/s11657-021-00971-0","journal-title":"Arch Osteoporos"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000713","article-title":"The impact of advanced glycation end products on bone properties in chronic kidney disease","volume":"30","author":"Damrath JG","year":"2021","unstructured":"Damrath JG, Creecy A, Wallace JM, Moe SM. The impact of advanced glycation end products on bone properties in chronic kidney disease. Curr Opin Nephrol Hypertens. 2021, 30:411-7. 10.1097\/MNH.0000000000000713","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqz006","article-title":"Advanced glycation end products: building on the concept of the \u201ccommon soil\u201d in metabolic disease","volume":"161","author":"Ruiz HH","year":"2019","unstructured":"Ruiz HH, Ramasamy R, Schmidt AM. Advanced glycation end products: building on the concept of the \u201ccommon soil\u201d in metabolic disease. Endocrinology. 2019, 161:bqz006. 10.1210\/endocr\/bqz006","journal-title":"Endocrinology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-015-9985-5","article-title":"Effects of collagen crosslinking on bone material properties in health and disease","volume":"97","author":"Saito M","year":"2015","unstructured":"Saito M, Marumo K. Effects of collagen crosslinking on bone material properties in health and disease. Calcif Tissue Int. 2015, 97:242-61. 10.1007\/s00223-015-9985-5","journal-title":"Calcif Tissue Int"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.508","article-title":"Management of multiple myeloma in the relapsed\/refractory patient","volume":"2017","author":"Sonneveld P","year":"2017","unstructured":"Sonneveld P. Management of multiple myeloma in the relapsed\/refractory patient. Hematology Am Soc Hematol Educ Program. 2017, 2017:508-17. 10.1182\/asheducation-2017.1.508","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-726703","article-title":"How I treat first relapse of myeloma","volume":"130","author":"Harousseau JL","year":"2017","unstructured":"Harousseau JL, Attal M. How I treat first relapse of myeloma. Blood. 2017, 130:963-73. 10.1182\/blood-2017-03-726703","journal-title":"Blood"},{"key":"ref32","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen LS","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M, et al.. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001, 7:377-87.","journal-title":"Cancer J"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen LS","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M, et al.. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003, 98:1735-44. 10.1002\/cncr.11701","journal-title":"Cancer"},{"key":"ref34","article-title":"Hematology: basic principles and practice","volume":"11","author":"Hoffman R","year":"2011","unstructured":"Hoffman R, Benz EJ, Silberstein LE. Hematology: basic principles and practice. N Engl J Med. 2011, 11:21-33.","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-009-0015-4","article-title":"The role of bisphosphonates in multiple myeloma","volume":"4","author":"Levy J","year":"2009","unstructured":"Levy J, Roodman GD. The role of bisphosphonates in multiple myeloma. Curr Hematol Malig Rep. 2009, 4:108-12. 10.1007\/s11899-009-0015-4","journal-title":"Curr Hematol Malig Rep"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos E","year":"2013","unstructured":"Terpos E, Morgan G, Dimopoulos MA, et al.. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013, 31:2347-57. 10.1200\/JCO.2012.47.7901","journal-title":"J Clin Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC myeloma IX): secondary outcomes from a randomised controlled trial","volume":"12","author":"Morgan GJ","year":"2011","unstructured":"Morgan GJ, Child JA, Gregory WM, et al.. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol. 2011, 12:743-52. 10.1016\/S1470-2045(11)70157-7","journal-title":"Lancet Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/164152-multiple-myeloma-and-the-role-of-bisphosphonates-in-its-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:55Z","timestamp":1707509155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/164152-multiple-myeloma-and-the-role-of-bisphosphonates-in-its-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.45270","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,14]]}}}